Strata Critical Medical (SRTA) Cash & Equivalents (2019 - 2026)

Strata Critical Medical has disclosed Cash & Equivalents across 8 years of filings, most recently posting $58.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 68.6% year-over-year to $58.7 million; the TTM figure through Mar 2026 stood at $58.7 million (up 68.6% YoY), while the FY2025 annual figure was $31.0 million, up 92.68% from the prior year.
• Cash & Equivalents rose to $58.7 million in Q1 2026, from $31.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SRTA reached as high as $186.6 million in Q2 2022 and fell as low as $263000.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $34.8 million (2025), against an average of $37.9 million.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 1572.24% — and 2025, when it plunged 98.69%.
• A 5-year view of Cash & Equivalents shows it stood at $3.1 million in 2022, then tumbled by 62.79% to $1.1 million in 2023, then jumped by 1300.0% to $16.1 million in 2024, then soared by 92.68% to $31.0 million in 2025, then jumped by 89.62% to $58.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $58.7 million, $31.0 million, and $263000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.